Cost Effectiveness of Imatinib Compared with Interferon-?? or Hydroxycarbamide for First-Line Treatment of Chronic Myeloid Leukaemia
- 1 January 2005
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 23 (5) , 515-526
- https://doi.org/10.2165/00019053-200523050-00010
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Cost–utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemiaBritish Journal of Cancer, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemiasThe Lancet Oncology, 2003
- The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic reviewHealth Technology Assessment, 2002
- Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic respondersBlood, 2001
- Chronic Myelogenous LeukemiaJAMA, 2001
- Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferonBritish Journal of Haematology, 2000
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic responseThe Lancet, 1995
- Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-α TherapyAnnals of Internal Medicine, 1995